Quantum Pharma PLC Appointment of Chief Financial Officer (3168R)

TIDMQP.

RNS Number : 3168R

Quantum Pharma PLC

08 December 2016

 
 For immediate release   8 December 2016 
 

Quantum Pharma Plc

('Quantum' or the 'Group')

Appointment of Chief Financial Officer

Quantum Pharma Plc (AIM: QP.), the service-led niche pharmaceutical developer, manufacturer and supplier to the health and care sectors, is pleased to announce the appointment of Gerard (Ged) Murray to the Board as Chief Financial Officer (CFO) with effect from 23 January 2017. Chris Rigg, Quantum's CEO, will continue in his joint role as CEO and CFO until that date.

Gerard brings with him a wealth of experience, having been finance director for a number of publicly quoted companies. He qualified as a Chartered Accountant with Arthur Andersen and spent over ten years serving as CFO and then CEO of Reg Vardy plc before joining Northgate plc as group finance director for a five year period. Both of these quoted companies experienced considerable growth during the periods that he served on their respective boards. Gerard also has sector experience from a period as group finance director of Immunodiagnostic Systems Holdings PLC. More recently he led the sale of Benfield Motor Group, a family owned motor retailer for GBP87.5 million to Lookers plc in September 2015 before joining Ardent Hire Solutions Limited, a private equity backed plant hire business, where he has been the CFO since April 2016.

Commenting on the appointment, Chris Rigg, CEO and CFO of Quantum Pharma Plc, said: "I am delighted that Ged is joining Quantum as our new CFO. He has an excellent track record and reputation, having worked as finance director for a number of well-known and respected public companies and will further strengthen and complement the Board. The Board joins me in welcoming him to Quantum and we look forward to benefiting from his considerable knowledge and experience in helping drive our focused and simplified business forward and generating value for our shareholders."

The following information is disclosed pursuant to Schedule Two paragraph (g) of the AIM Rules for Companies. Gerard Thomas Murray, age 53 years, has been a director of the following companies during the five years preceding the date of this announcement:

 
 Current directorships   Past directorships 
----------------------  -------------------------------------- 
 Wren Topco Limited      Addison Motor Company (02/09/2015) 
 Transflex Vehicle       IDS plc (30/11/2012) 
  Rental Limited 
 One Call Hire Capital   Sonik Sports Limited (12/09/2012) 
  Limited 
 Fork Rent Limited       Peter Vardy Holdings Limited 
                          (30/05/2012) 
 One Call Hire Limited   Vardy Property Group Limited 
                          (02/04/2012) 
 One Call Tool Hire      Addison TPS Limited (02/09/2015) 
  Limited 
 Ardent Hire Solutions   The King's School Tynemouth 
  Limited                 Limited (02/09/2015) 
 Wren EBT Limited        J.M Sloan & Company Limited 
                          (02/09/2015) 
 Wren Buyerco Limited    Squires Capital Limited (02/09/2015) 
 Wren Rollco Limited     Benfield Motor Group Limited 
                          (02/09/2015) 
                         Benfield Pension Motor Group 
                          Limited (02/09/2015) 
                         Immunodiagnostics Systems 
                          Holdings Public Limited Company 
                          (30/11/2012) 
                         ST Ebba Capital Limited (02/09/2015) 
                         J M Sloan & Company (Car Hire) 
                          Limited (02/09/2015) 
                         Addison Motors Limited (02/09/2015) 
                         Rosedale Finance & Leasing 
                          Limited (02/09/2015) 
                         Harpers Carlisle limited (02/09/2015) 
                         Colebrook & Burgess Limited 
                          (02/09/2015) 
                         Colebrook & Burgess (Teeside) 
                          Limited (02/09/2015) 
                         Colebrook & Burgess (North 
                          Shields) Limited (02/09/2015) 
                         Colebrook & Burgess (Wallsend) 
                          Limited (02/09/2015) 
                         Colebrook & Burgess Holdings 
                          Limited (02/09/2015) 
                         Immunodiagnostics Systems 
                          Limited (30/11/2012) 
                         The Great North Bakery Limited 
                          (02/04/2012) 
                         Peter Vardy Limited (30/05/2012) 
                         Vardy Family Office Limited 
                          (02/04/2012) 
                         Vardy Ventures Limited (02/04/2012) 
                         Vardy Property (Teesside) 
                          Limited (02/04/2012) 
                         Vardy Property Aberdeen Limited 
                          (02/04/2012) 
                         Carolina Court (VPG) Limited 
                          (02/04/2012) 
                         Macleods of Perth Limited 
                          (30/05/2014) 
                         Vardy Property 100 Limited 
                          (02/04/2012) 
                         Vardy Properties (02/04/2012) 
                         Elswick (vpg) limited (02/04/2012) 
 

There is no further information to be disclosed pursuant to Rule 17 or Schedule Two paragraph (g) of the AIM Rules for Companies.

- Ends -

For further information:

 
 Quantum Pharma Plc 
 Ian Johnson, Chairman                     Tel: [phone] 
  Chris Rigg, CEO and CFO                            279 404 
  Craig Swinhoe, Group Strategic    www.quantumpharmaplc.com 
  Projects Director and Company 
  Secretary 
 N+1 Singer (NOMAD and Broker)               Tel: +44 (0) 20 
                                                   7496 3000 
 Sandy Fraser / Nick Owen /                 www.n1singer.com 
  James White 
 
 Media enquiries: 
 Buchanan 
 Henry Harrison-Topham / Sophie              Tel: +44 (0) 20 
  Cowles / Steph Watson                            7466 5000 
 [e-mail]           www.buchanan.uk.com 
 

Notes to Editors

Quantum Pharma Plc is a service-led, niche pharmaceutical developer, manufacturer and supplier to the retail pharmacy, pharmaceutical wholesaler, hospital, homecare and care home markets. Quantum Pharma operates through three divisions: Specials, Niche Pharmaceuticals and Medication Adherence, offering a portfolio of innovative and complementary products and services.

Specials comprises three business units (Quantum Pharmaceutical, UL Medicines and Quantum Aseptics Services). This division manufactures, procures and supplies bespoke specials; batch made specials; aseptically prepared sterile intravenous medicines; imported medicines and special obtain products in response to a request from a prescriber for a bespoke medicine or special product to optimise patient treatment. The division offers an unrivalled and constantly expanding range of products. It has a customer-focused, service-driven business model, which provides shorter lead times than any of its competitors.

Niche Pharmaceuticals comprises three business units (Colonis, Lamda and PERN Consumer Products). This division is a product development and commercialisation business focusing on taking niche drugs through the regulatory pathway to achieve regulated status (licensed product or medical device). The division uses the excellent visibility of trends in the UK pharmacy and hospital markets gained through our Specials and Medication Adherence divisions, to allow early identification of the market opportunity to take products from unlicensed to licensed status. The division has a growing portfolio and pipeline of products that fit this unlicensed to licensed pathway, as well as complementary generic, generic plus or medical devices intended to meet unmet patient needs across a number of therapeutic areas.

Medication Adherence comprises two business units (Biodose(R) and Biodose Services(R)). This division provides products and services to enhance the likelihood of a patient adhering to a medication regime, patient-focused homecare services and services to pharmaceutical companies. It owns Biodose(R), the only medication delivery system on the market that accommodates both liquid and solid doses. Biodose Connect(TM) takes patient safety and adherence to the next level by enabling remote monitoring of adherence to medication regimes. The division also operates a range of specialist patient-focused homecare services to the NHS, private clinics and pharmaceutical companies and provides the Group with exposure to the homecare and supported living sectors of the care pathway, complementing the focus of the remainder of the Group.

For further information, please visit www.quantumpharmaplc.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

BOAGIBDDRXGBGLI

(END) Dow Jones Newswires

December 08, 2016 03:45 ET (08:45 GMT)